Infectiologic differential diagnosis of chronic Lyme disease and so ...

More documents

Recommendations

Info

[310] Sorvillo FJ, Lieb LE, Waterman SH. Incidence of campylobacteriosis among patients with AIDS in Los Angeles County. J Acquir Immune Defic Syndr 1991; 4(6): 598-602. [311] Melamed I, Bujanover Y, Igra YS, Schwartz D, Zakuth V, Spirer Z. Campylobacter enteritis in normal and immunodeficient children. Am J Dis Child 1983; 137(8): 752-3. [312] Taylor DE, Chang N. In vitro susceptibilities of Campylobacter jejuni and Campylobacter coli to azithromycin and erythromycin. Animicrob Agents Chemother 1991; 35(9): 1917-8. [313] Gaunt PD, Piddock LJ. Ciprofloxacin resistant Campylobacter spp. in humans: an epidemiological and laboratory study. J Antimicrob Chemother 1996; 37(4): 747-57. [314] Lariviere LA, Gaudreau CL, Turgeon FF. Susceptibility of clinical isolates of Campylobacter jejuni to twenty-five antimicrobila agents. J Antimicrob Chemother 1986; 18(6): 681-5. [315] Bonetti B, Monaco S, Ferrari S, Tezzon F, Rizzuto N. Demyelinating polyradiculoneuritis following Coxiella burnetti infection (Q fever). Ital J Neurol Sci 1991; 12(4): 415-7. [316] Walid MS, Ajjan M, Ulm AJ. Subacute Transverse myelitis with Lyme profile dissociation. Ger Med Sci 2008; 6: Doc04. [317] Bernit E, Pouget J, Janbon F et al. Neurological involvement in acute Q fever: a report of 29 cases and review of the literature. Arch Intern Med 2002; 162(6): 693-700. [318] Shaked Y, Samra Y. Q fever meningoencephalitis associated with bilateral abducens nerve paralysis, bilateral optic neuritis and abnormal cerebrospinal fluid findings. Infection 1989; 17(6): 394-5. 94
[319] Brooks RG, Licitra CM, Peacock MG. Encephalitis caused by Coxiella burnetii. Ann Neurol 1986; 20(1): 91-3. [320] Kofteridis DP, Mazokopakis EE, Tselentis Y, Gikas A. Neurological complications of acute Q fever infection. Eur J Epidemiol 2004; 19(11): 1051- 4. [321] Biswas S, Raoult D, Rolain J-M. Molecular Characterization of Resistance to Macrolides in Bartonella henselae. Anticibrobial Agents and Chemotherapy 2006; 3192-93. [322] Kordick DL, Papich MG, Breitschwerdt EB. Efficacy of Enrofloxacin or Doxycycline for Treatment of Bartonella henselae or Bartonella clarridgeiae Infection in Cats. Anticibrobial Agents and Chemotherapy 1997; 2448-55. [323] Rolain JM, Brouqui P, Koehler JE, Maguina C, Dolan MJ, Raoult D. Minireview. Recommendations for Treatment of Human Infections Caused by Bartonella Species. Anticibrobial Agents and Chemotherapy 2004; 1921-33. [324] Musso D, Drancourt M, Raoult D. Lack of bactericidal effect of antibiotics except aminoglycosides on Bartonella (Rochalimaea) henselae. The British Society for Antimicrobial Chemotherapy 1995. [325] Pendle S, Ginn A, Iredell J. Antibicrobial susceptibility of Bartonella henselae using Etest methodology. Anticibrobial Agents and Chemotherapy 2006; 761- 63. [326] Dörbecker C, Sander A, Oberle K, Schülin-Casonato T. In vitro susceptivility of Bartonella species in 17 antimicrobial compounds: comparison of Etest and agar dilution. Anticibrobial Agents and Chemotherapy 2006; 784-88. [327] Biswas S, Maggi RC, Papich MG, Keil D, Breitschwerdt EB. Comparative Activity of Pradofloxacin, Enrofloxacin, and Azithromycin against Bartonella 95
Page 1 and 2:
Infectiologic differential diagnosi
Page 3 and 4:
3 Anamnistically, one has to consid
Page 5 and 6:
Table 2 LD coinfections (not tick-b
Page 7 and 8:
Table 5 Bartonellosis’ infection
Page 9 and 10:
Table 6 Main disease manifestations
Page 11 and 12:
11 Fig. 1. Erythrocytes infected wi
Page 13 and 14:
13 Bartonellae are localized in ery
Page 15 and 16:
ESR und CRP elevated Hypercalcemia
Page 18 and 19:
Table 9 Antibiotic treatment of bar
Page 20 and 21:
antibiosis is that the antibiotic i
Page 22 and 23:
The laboratory diagnostics for Chla
Page 24 and 25:
The arthritis occurs in 1% of the u
Page 26 and 27:
In the differential diagnosis of Ly
Page 28 and 29:
Late phase: - Reactive arthritis -
Page 30 and 31:
the depiction of chronic yersiniosi
Page 32 and 33:
In Yersinia-PCR-positive patients,
Page 34 and 35:
- Incubation period 3 weeks - Atypi
Page 36 and 37:
system, of the skin and other organ
Page 38 and 39:
- Ehrlichia chaffeensis [1] - Anapl
Page 40 and 41:
Since seroprevalence merely express
Page 42 and 43:
B. microti is the predominant patho
Page 44 and 45: epresent a major health hazard and
Page 46 and 47: The decisive diagnostic information
Page 48 and 49: Probable: IFA IgG 1:1024 and one of
Page 50 and 51: The main manifestation of the Campy
Page 52 and 53: The term “reactive arthritis” i
Page 54 and 55: In the diagnosis of a “reactive a
Page 56 and 57: Table 27 Disease manifestations of
Page 58 and 59: addition, other pathogens discussed
Page 60 and 61: [8] Schouls LM, Van De Pol I, Rijpk
Page 62 and 63: [25] Hermanowska-Szpakowicz T, Skot
Page 64 and 65: [43] Bakken JS, Krueth JK, Lund T,
Page 66 and 67: [60] Fox LM, Wingerter S, Ahmed A e
Page 68 and 69: [80] Marra CM. Neurologic complicat
Page 70 and 71: [100] Pulliainen AT, Dehio C. Barto
Page 72 and 73: [118] Bass JW, Freitas BC, Freitas
Page 74 and 75: [137] Gaydos CA, Roblin PM, Hammers
Page 76 and 77: [155] Cover TL, Aber RC. Yersinia e
Page 78 and 79: multi-organ donors for the presence
Page 80 and 81: [190] Straubinger RK, Straubinger A
Page 82 and 83: [208] Bitnun A, Ford-Jones E, Blase
Page 84 and 85: patients with reactive and undiffer
Page 86 and 87: [242] Appelbaum PC, Gillespie SH, B
Page 88 and 89: pneumoniae infection associated wit
Page 90 and 91: [276] Thomas NH, Collins JE, Robb S
Page 92 and 93: [294] File TM Jr, Segreti J, Dunbar
Page 96 and 97: henselae Isolates Collected from Ca
Page 98 and 99: [345] Raoult D, Levy PY, Harlé JR,
show all

Infectiologic differential diagnosis of chronic Lyme disease and so ...

Create successful ePaper yourself

Delete template?

Save as template?